NCT05048082View on ClinicalTrials.gov

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Lung Cancer
Interventions
DRUG

pegsitacianine

An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).

PROCEDURE

Tumor resection surgery

Standard of care surgical removal of cancerous lung lesion

Trial Locations (2)

19104

Hospital of the University of Pennsylvania, Philadelphia

77030

The University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

OncoNano Medicine, Inc.

INDUSTRY

NCT05048082 - A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies | Biotech Hunter | Biotech Hunter